Hansa Medical in brief

0
Rate this post

Hansa Medical is a biopharmaceutical firm creating unique immunomodulatory enzymes for organ transplantation and severe autoimmune illness. The Company’s lead item, imlifidase, is a proprietary, antibody-degrading enzyme in late-stage medical advancement for kidney transplant individuals, with the possibility for further growth in other strong body organ transplantation and intense autoimmune indicators. Hansa also has a strong pipe of preclinical jobs, consisting of NiceR, where the Firm is creating unique immunoglobulin-cleaving enzymes for repeat dosing in relapsing autoimmune illness as well as oncology. Hansa Medical is based in Lund, Sweden, and its shares are listed on NASDAQ Stockholm (HNSA).

Secret truths

  • Innovative and encouraging pipeline
  • Imlifidase– prospect drug in a number of Stage 2 tests in kidney transplantation
  • NiceR – Unique immunoglobulin cleaving enzymes for Repeat dosing
  • EnzE – Enzyme based antibody Enhancement
  • Premium global scientific network within hair transplant as well as immunology
  • Board of Supervisors with long pharma as well as biotech experience
  • Small as well as cutting-edge team (Approx. 60 workers).
  • Based in Lund, Sweden.
  • Detailed on NASDAQ Stockholm (ticker: HNSA).
  • 759 MSEK in cash and also short term financial investments, March 31, 2019.

LÄMNA ETT SVAR

Vänligen ange din kommentar!
Vänligen ange ditt namn här